Edwards Lifesciences Corporation $EW Shares Sold by Erste Asset Management GmbH

Erste Asset Management GmbH lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 50.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 21,520 shares of the medical research company’s stock after selling 22,016 shares during the quarter. Erste Asset Management GmbH’s holdings in Edwards Lifesciences were worth $1,661,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at $266,000. Arkadios Wealth Advisors purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $300,000. Premier Path Wealth Partners LLC increased its position in shares of Edwards Lifesciences by 10.4% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 4,210 shares of the medical research company’s stock worth $329,000 after purchasing an additional 395 shares during the last quarter. Keybank National Association OH raised its holdings in Edwards Lifesciences by 0.6% in the 2nd quarter. Keybank National Association OH now owns 36,172 shares of the medical research company’s stock valued at $2,829,000 after buying an additional 233 shares during the period. Finally, Assetmark Inc. lifted its position in Edwards Lifesciences by 344.7% in the second quarter. Assetmark Inc. now owns 2,735 shares of the medical research company’s stock valued at $214,000 after buying an additional 2,120 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $86.47 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a market cap of $50.22 billion, a price-to-earnings ratio of 47.25, a price-to-earnings-growth ratio of 2.26 and a beta of 0.94. The stock’s 50-day moving average is $82.74 and its two-hundred day moving average is $81.25. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the previous year, the business posted $0.59 EPS. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 67,804 shares of company stock valued at $5,711,242. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EW. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. BTIG Research reiterated a “buy” rating and issued a $103.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 11th. UBS Group restated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Tuesday, January 20th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.